Pancreatic Cancer Research

ResearcherLanzhou University Second HospitalActive in the last 2 years

Zuoyi Jiao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1942-0905; OpenAlex author ID A5062004576. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
14
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 4 papers

Papers 10

  1. UBE2T-Driven p53 Degradation Rewires Glycolysis to Orchestrate Lactylation-Mediated CAFs Activation and ECM Deposition in Pancreatic Cancer. Last author DOI 10.1002/advs.202514933↗
  2. UBE2T-driven lipid metabolic reprogramming links chronic inflammation to pancreatic cancer progression. Last author DOI 10.1016/j.pan.2026.10.028↗
  3. USP20 promotes CD8+ T cell exhaustion and impairs KRAS G12D inhibitor efficacy by orchestrating cholesterol metabolism and autophagy in pancreatic cancer. Last author DOI 10.1136/gutjnl-2026-338277↗
  4. USP20-Driven Cholesterol Metabolism Links Inflammatory Signaling to Malignancy and Stromal Coevolution in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-25-1228↗
  5. A novel nanocarrier based on natural polyphenols enhancing gemcitabine sensitization ability for improved pancreatic cancer therapy efficiency. Last author DOI 10.1016/j.mtbio.2025.101463↗
  6. KRAS G12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC. Last author DOI 10.1016/j.xcrm.2025.101966↗
  7. Self-assembled metal-polyphenolic based multifunctional nanomedicine to improve therapy treatment of pancreatic cancer by inhibition of glutamine metabolism. Last author DOI 10.1016/j.colsurfb.2024.114162↗
  8. Therapeutic potential of SHCBP1 inhibitor AZD5582 in pancreatic cancer treatment. Last author DOI 10.1111/cas.16059↗
  9. Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replication Stress. Last author DOI 10.1053/j.gastro.2023.02.025↗
  10. Survival Benefit of Metformin Use for Pancreatic Cancer Patients Who Underwent Pancreatectomy: Results From a Meta-Analysis. Co-author DOI 10.3389/fmed.2020.00282↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiangyan Jiang · 6 shared papers, 2023–2026 · strength 1.25
  2. Yuman Dong · 4 shared papers, 2024–2026 · strength 0.88
  3. Zeyuan Yu · 4 shared papers, 2023–2026 · strength 0.80
  4. Yiwei Dai · 3 shared papers, 2024–2025 · strength 0.73
  5. Yong Ma · 3 shared papers, 2026 · strength 0.69
  6. Jieru Li · 2 shared papers, 2024–2025 · strength 0.47
  7. Lixia Xiao · 1 shared paper, 2026 · strength 0.33
  8. Tao Wang · 2 shared papers, 2023–2025 · strength 0.33
  9. Junhong Guan · 2 shared papers, 2023–2025 · strength 0.33
  10. Zhijian Ma · 1 shared paper, 2024 · strength 0.26
  11. Rufu Chen · 1 shared paper, 2026 · strength 0.23
  12. Junqiang Zhang · 1 shared paper, 2020 · strength 0.13
  13. Jichun Ma · 1 shared paper, 2020 · strength 0.13
  14. Yumin Li · 1 shared paper, 2020 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.